Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in Cushing's Disease
NCT04339751Phase 2Withdrawn
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Apr 2025
- Primary completion
- Apr 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vorinostat in Cushing's disease (CD), sponsored by National Institute of Neurological Disorders and Stroke. Planned start Apr 2025; status: withdrawn.
02
Drugs
vorinostat
03
Conditions
Cushing's disease (CD)
Beyond the preview
Go deeper on NCT04339751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04339751.